PriceTargets.com logo

IMV - IMV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00 As of 04/29/2023 12:59 AM ET
+0 (0.00%)

This chart shows the closing price for IMV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IMV Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMV

Analyst Price Target is C$0.00
This price target is based on 1 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.

This chart shows the closing price for IMV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in IMV. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/2/2023HC WainwrightDowngradeBuy ➝ Neutral
12/21/2022HC WainwrightReiterated RatingBuyC$65.00
8/11/2022HC WainwrightReiterated RatingBuyC$130.00
6/22/2022HC WainwrightReiterated RatingBuyC$130.00
6/7/2022HC WainwrightReiterated RatingBuyC$130.00
5/13/2022Echelon Wealth PartnersReiterated RatingBuy
5/13/2022HC WainwrightReiterated RatingBuyC$130.00
4/13/2022HC WainwrightReiterated RatingBuyC$130.00
2/25/2022HC WainwrightReiterated RatingBuyC$130.00
12/22/2021Raymond JamesReiterated RatingHoldC$17.50
11/12/2021National BanksharesLower TargetSector PerformC$42.50 ➝ C$25.00
11/11/2021HC WainwrightReiterated RatingBuyC$130.00
9/22/2021Cantor FitzgeraldInitiated CoverageBuyC$40.00
8/11/2021National Bank FinancialReiterated RatingSector Perform Market Weight
7/16/2021Raymond JamesLower TargetMarket PerformC$25.00
5/13/2021Raymond JamesReiterated RatingMarket PerformC$36.00
5/13/2021National Bank FinancialLower TargetSector Perform ➝ Sector PerformC$52.50 ➝ C$42.50
5/13/2021National BanksharesLower TargetSector PerformC$52.50 ➝ C$42.50
3/18/2021Leede Jones GabReiterated RatingSpeculative Buy
3/18/2021Raymond JamesReiterated RatingMarket PerformC$30.00
3/18/2021National BanksharesLower TargetSector PerformC$52.50
12/4/2020Raymond JamesReiterated RatingMarket PerformC$30.00
8/7/2020National Bank FinancialDowngradeOutperform ➝ Sector PerformC$50.00 ➝ C$70.00
5/22/2020Raymond JamesReiterated RatingMarket PerformC$30.00
4/1/2020National Bank FinancialLower TargetOutperformC$92.50 ➝ C$50.00
3/31/2020B. RileyDowngradeBuy ➝ Neutral
3/5/2020National Bank FinancialLower TargetC$105.00 ➝ C$92.50
11/26/2019OppenheimerSet TargetOutperformC$90.00
5/29/2019B. RileyReiterated RatingBuy
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2023
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

IMV logo
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: C$1.12
Low: C$1.12
High: C$1.12

52 Week Range

Now: N/A

Volume

15,761 shs

Average Volume

56,822 shs

Market Capitalization

C$13.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of IMV?

The following sell-side analysts have issued research reports on IMV in the last twelve months: HC Wainwright.
View the latest analyst ratings for IMV.

What is the current price target for IMV?

0 Wall Street analysts have set twelve-month price targets for IMV in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for IMV in the next year.
View the latest price targets for IMV.

What is the current consensus analyst rating for IMV?

IMV currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IMV, but not buy more shares or sell existing shares.
View the latest ratings for IMV.

What other companies compete with IMV?

Other companies that are similar to IMV include Aeterna Zentaris, Resverlogix, Sirona Biochem, Antibe Therapeutics and Neptune Wellness Solutions. Learn More about companies similar to IMV.

How do I contact IMV's investor relations team?

IMV's physical mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company's listed phone number is +1-902-4921819. The official website for IMV is www.imvaccine.com. Learn More about contacing IMV investor relations.